Background: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap syndrome are rare severe cutaneous adverse reactions associated with high mortality.
Objectives: To estimate incidence and describe trends of SJS/TEN hospitalizations in the United States and to describe the clinical, demographic, and geographic characteristics of affected patients and risk factors for mortality.
Methods: We utilized hospitalization data from the 2010 to 2020 National Inpatient Sample. SJS, SJS-TEN overlap syndrome, and TEN were identified by International Classification of Diseases, 9th Revision and International Classification of Diseases, 10th Revision codes and analyzed by logistic regression.
Results: We identified 51,040 hospitalizations involving SJS/TEN. Amog those, 37,283 (73.0%) were for SJS only, 7818 (15.3%) were for SJS-TEN overlap syndrome, and 7160 (14.0%) were for TEN only. Overall, SJS/TEN hospitalization rates declined over time, 2010 to 2020 ( < .05). Mortality rates of the SJS group, SJS-TEN overlap syndrome group, and TEN group were 5.4%, 14.4%, and 15.3%, respectively. Increasing age, chronic kidney disease, pneumonia, sepsis, and malignant neoplasm were all significantly associated with increased odds of mortality ( < .05). Non-Hispanic White racial/ethnic identification was associated with decreased odds of mortality ( < .05).
Limitations: Lack of standardization for diagnostic criteria.
Conclusions: Risk factors identified in this study lay the groundwork for improvement in SJS/TEN mortality prediction scoring.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413346 | PMC |
| http://dx.doi.org/10.1016/j.jdin.2023.06.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe Cutaneous Toxicity in A 67-Year-Old Patient with Metastatic Urothelial Carcinoma Undergoing Therapy with Enfortumab Vedotin and Pembrolizumab.
Eur J Case Rep Intern Med
November 2024
Department of Oncology, Cantonal Hospital Baselland, Liestal, Switzerland.
Article Synopsis
- Enfortumab vedotin combined with pembrolizumab (EV+P) shows effectiveness in treating metastatic urothelial carcinoma, but can lead to severe skin reactions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
- A case is presented of a 67-year-old man who developed SJS/TEN overlap after EV+P therapy, demonstrating the importance of recognizing and treating severe skin toxicities early in patients with additional health issues.
- Effective management requires quick action with steroids and a multidisciplinary approach, alongside vigilant monitoring and reporting of adverse effects to enhance patient safety.
Prognosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Cohort Study of 216 Patients in an Inpatient Dermatology Department.
Dermatology
November 2024
Faculty of Medicine, Vietnam National University, Ho Chi Minh City, Vietnam.
Introduction: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions. However, only a few studies have investigated the clinicodemographic and laboratory parameters predicting SJS and TEN outcomes other than mortality, such as severe complications or increased length of hospital stays. Our objectives are to identify admission risk factors predictive of severe complications and the accompanying clinical or biochemical markers associated with prolonged hospitalization.
View Article and Find Full Text PDFPrognostic significance of the systemic immune-inflammation index in patients with Steven-Johnson syndrome and toxic epidermal necrolysis.
Clin Exp Dermatol
December 2024
Division of Dermatology, Department of Medicine, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia.
Inflammatory markers such as neutrophil-lymphocyte ratio (NLR) and eosinophil count are known prognostic indicators for the severity of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). This study explores the correlation of systemic immune-inflammation index (SII), platelet-lymphocyte ratio (PLR) and NLR with Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) and patient outcomes. A retrospective audit of 34 patients with SJS/TEN (25 SJS, 3 SJS/TEN overlap, 6 TEN) was conducted from 2018 to 2022.
View Article and Find Full Text PDFToxic epidermal necrolysis caused by phenobarbital: a case report and literature review.
Front Pharmacol
August 2024
Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, China.
Article Synopsis
- Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are serious immune reactions, and this study focused on a case involving a woman taking phenobarbital for seizures who developed TEN.
- The case was analyzed alongside existing literature, revealing that there were 19 reported cases of phenobarbital-induced SJS/TEN, with a notable portion resulting in fatalities, particularly among younger patients.
- The findings emphasize the need for close monitoring of patients starting phenobarbital treatment, especially those with a history of asthma, since severe skin reactions can occur early in treatment even in patients who test negative for certain genetic markers.
Lamotrigine Emerging as a Driver of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An 8-Year Retrospective Study.
Burns
November 2024
Department of Surgery, Connecticut Burn Center, Bridgeport Hospital, Bridgeport, CT, United States. Electronic address:
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) represent severe manifestations of a potentially life-threatening spectrum defined by a desquamating rash of the skin and mucous membranes. This study was prompted by the observed increase in the off-label use of lamotrigine as a causal agent in SJS/TEN in our regional burn center.
Methods: A retrospective cohort of 48 patients presenting to the Connecticut Burn Center from 2015-2022 with suspicion for SJS/TEN were reviewed for age, sex, causative drug, presenting symptoms, hospital course, biopsy confirmation, length of stay, comorbidities, and 30-day mortality.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!